Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6105713 | 0.93 | HTR1A (0.57) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL6108012 | 0.89 | HTR1A (0.65) | HTR1ASLC6A4DRD2HTR2AADRA1D | |
| SCHEMBL6105063 | 0.83 | SLC6A4 (0.50) | HTR1ASLC6A4 | |
| SCHEMBL5845217 | 0.82 | HTR1A (0.66) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL6629048 | 0.82 | HTR1A (0.59) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL6628211 | 0.80 | HTR1A (0.65) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL6629700 | 0.80 | HTR1A (0.65) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL7122366 | 0.79 | HTR1A (0.58) | HTR1ASLC6A4DRD2HTR2ATDO2 | |
| SCHEMBL6628881 | 0.79 | HTR1A (0.61) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL14573474 | 0.79 | HTR1A (0.72) | HTR1ASLC6A4DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987117-B2 | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine | WYETH (US) | 2006-01-17 | — | — | US | claimed |
| US-20040058953-A1 | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine | TRAN MEGAN (US) | 2004-03-25 | — | — | US | claimed |
| US-6656950-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-12-02 | — | — | US | claimed |
| US-20020183355-A1 | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine | WYETH (US) | 2002-12-05 | — | — | US | claimed |
| WO-2002085911-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 1,4-DIOXINO[2,3-b]PYRIDINE | WYETH (US) | 2002-10-31 | — | — | WO | claimed |
| US-6987117-B2 | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine | WYETH (US) | 2006-01-17 | — | — | US | disclosed |
| US-20040058953-A1 | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine | TRAN MEGAN (US) | 2004-03-25 | — | — | US | disclosed |
| US-6656950-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-12-02 | — | — | US | disclosed |
| US-20020183355-A1 | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine | WYETH (US) | 2002-12-05 | — | — | US | disclosed |
| WO-2002085911-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 1,4-DIOXINO[2,3-b]PYRIDINE | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183355-A1 | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine | OPRD1, HSD17B11, OPRM1 | HTR1A 11/4885SLC6A4 211/4885DRD2 31/4885 |
| US-20040058953-A1 | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine | OPRD1, HSD17B11, OPRM1 | HTR1A 11/4885SLC6A4 211/4885DRD2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.